Genetic evidence for serum amyloid P component as a drug target in neurodegenerative disorders
Open Biology · 2024
DOI: 10.1098/rsob.230419 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Open Biology, 2024. Verfasst von A Floriaan Schmidt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular Science, Faculty of Population Health, University College London, 69-75 Chenies Mews, London WC1E 6HX, UK. Hauptthemen laut MEDLINE: Genome-Wide Association Study, Neurodegenerative Diseases, Serum Amyloid P-Component. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, NLM NIH HHS, UKRI/NIHR Multimorbidity Fund Mechanism and Therapeutics Research Collaborative.
Abstract (Originalsprache)
The mechanisms responsible for neuronal death causing cognitive loss in Alzheimer's disease (AD) and many other dementias are not known. Serum amyloid P component (SAP) is a constitutive plasma protein, which is cytotoxic for cerebral neurones and also promotes formation and persistence of cerebral A β amyloid and neurofibrillary tangles. Circulating SAP, which is produced exclusively by the liver, is normally almost completely excluded from the brain. Conditions increasing brain exposure to SAP increase dementia risk, consistent with a causative role in neurodegeneration. Furthermore, neocortex content of SAP is strongly and independently associated with dementia at death. Here, seeking genomic evidence for a causal link of SAP with neurodegeneration, we meta-analysed three genome-wide association studies of 44 288 participants, then conducted cis -Mendelian randomization assessment of associations with neurodegenerative diseases. Higher genetically instrumented plasma SAP concentrations were associated with AD (odds ratio 1.07, 95% confidence interval (CI) 1.02; 1.11, p = 1.8 × 10 −3 ), Lewy body dementia (odds ratio 1.37, 95%CI 1.19; 1.59, p = 1.5 × 10 −5 ) and plasma tau concentration (0.06 log 2 (ng l −1 ) 95%CI 0.03; 0.08, p = 4.55 × 10 −6 ). These genetic findings are consistent with neuropathogenicity of SAP. Depletion of SAP from the blood and the brain, by the safe, well tolerated, experimental drug miridesap may thus be neuroprotective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cardiovascular Science, Faculty of Population Health, University College London, 69-75 Chenies Mews, London WC1E 6HX, UK.
- UCL British Heart Foundation Research Accelerator, 69-75 Chenies Mews, London WC1E 6HX, UK.
- Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam UMC, locatie AMC Postbus 22660, 1100 DD Amsterdam, Zuidoost, The Netherlands.
- Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
- Wolfson Drug Discovery Unit, Division of Medicine, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.
- UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, Queen Square, London WC1N 3BG, UK.
ORCID-Profile: A Floriaan Schmidt, Aroon D Hingorani, Mark B Pepys
Förderung
- British Heart Foundation
- NLM NIH HHS
- UKRI/NIHR Multimorbidity Fund Mechanism and Therapeutics Research Collaborative
- BHF
Zitieren
APA
Schmidt, A. F., Finan, C., Chopade, S., Ellmerich, S., Rossor, M. N., Hingorani, A. D., & Pepys, M. B. (2024). Genetic evidence for serum amyloid P component as a drug target in neurodegenerative disorders. Open Biology. https://doi.org/10.1098/rsob.230419
Vancouver
Schmidt AF, Finan C, Chopade S, Ellmerich S, Rossor MN, Hingorani AD, et al. Genetic evidence for serum amyloid P component as a drug target in neurodegenerative disorders. Open Biology. 2024. doi:10.1098/rsob.230419
BibTeX
@article{Schmidt2024,
author = {Schmidt, A Floriaan and Finan, Chris and Chopade, Sandesh and Ellmerich, Stephan and Rossor, Martin N and Hingorani, Aroon D and Pepys, Mark B},
title = {Genetic evidence for serum amyloid P component as a drug target in neurodegenerative disorders},
journal = {Open Biology},
year = {2024},
doi = {10.1098/rsob.230419}
}
EUVIMED